Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis. First, let’s talk about generalized pustular psoriasis ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Steven R. Feldman, MD, PhD; Megan H. Noe, MD, MPH, MSCE Drs Steve Feldman and Megan Noe fill in the gaps about pustular psoriasis, a relatively rare but serious condition that can be tough to diagnose ...

Mark G. Lebwohl, MD, discusses how IL-36 mutations can play a part in disease presentation and how IL-17 and IL-23 pathways are more often implicated in plaque psoriasis. Aaron Farberg, MD, and Maria ...

Dermatology drugmaker Leo Pharma and the scattering of patients across the globe with rare skin disease generalized pustular psoriasis (GPP) are circling Aug. 13 on their calendars as the second ...

Generalized pustular psoriasis (GPP) is a rare, life-threatening skin condition for which there are no approved treatments. It is characterized by episodes of widespread eruptions of painful, sterile ...

A team from Nagoya University in Japan has identified previously unidentified gene variants that are associated with the development of generalized pustular psoriasis (GPP). The team's findings, ...

Pustular psoriasis of pregnancy (PPP) is a rare dermatosis of pregnancy that can lead to life-threatening maternal and fetal complications. Risk of recurrence in subsequent pregnancies is high, with ...

This page lists all known medications that could potentially lead to 'Pustular psoriasis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly more healthcare visits and costs than patients with plaque psoriasis alone. Researchers ...

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...